Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma

NCT02576665 is registered in ClinicalTrials.gov with Tocagen Inc. as lead sponsor.

NCT NCT02576665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma
Lead sponsor
Tocagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2016
Completion date
December 20, 2019
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer, head and neck cancer, idh1 mutated or mgmt methylated recurrent hgg (not recruiting), idh1 mutated solid tumors, lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, sarcoma, triple negative breast cancer